1RIECHERS H, KLINGE D, AMBERG W, et al. New carboxylic acid derivatives, their preparation and their use: EP, 785926[P]. 1996 - 04 - 25.
2RIECHERS H, ALBRECHT HP, AMBERG W, et al. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists [J]. J Med Chem, 1996, 39:2123 - 2128.
3BARST R J.A review of pulmonary arterial hypertension:role of ambrisentan[J]. Vasc Health Risk Manage, 2007, 3(1) : 11 - 22.
4VATTER H, ZIMMERMANN M, JUNG C, et al. Effect of the novel endothelin(A) receptor antagonist LU 208075 on contraction and relaxation of isolated rat basilar artery[J]. Clin Sci, 2002,103 Suppl(48) :408S-413S.
5GALIE N, BADESCH D, OUDIZ R, et al. Ambrisentan therapy for pulmonary arterial hypertension[J] .J Am Coll Cardiol, 2005, 46 (3) : 529 - 535.
5Nestl B M,Glueck S M,Hall M,et al.Eur J Org Chem[J],2006,(20):4573-4577.
6Blicke F F,Faust J A.J Am Chem Soc[J],1954,76 (12):3157-3159.
7Vatter H,Zimm Ermann M,Jung C, et al. Effect of the novel en- dothelin( A ) receptor antagonist LU 208075 on contraction and relaxation of isolated rat basilar artery [ J ]. Clin Sci, 2002, 103 (48) :408S-413S.
8Vatter H, Seifert V. Ambfisentan, a non-peptide endothelin receptor antagonist[ J]. Cardiovasc Drug Rev,2006,24( 1 ) :63.
10Narayana MB, Chandrasekhar KB, Rao BM. A validated specific stability-indicating RP-HPLC assay method for ambrisentan and its related substances[ J]. J Chromatogr Sci,2014,52(8) :818 825.
